To investigate if the cooperation between the Rgr oncogene and the inactivation of INK4b (a CDK inhibitor), as described previously in a sarcoma model, would be operational in a lymphoid system in vivo, we generated a transgenic/knockout murine model. Transgenic mice expressing the Rgr oncogene under a CD4 promoter were crossed into a p15 INK4b -deficient background. Unexpectedly, mice with a complete ablation of both p15 INK4b alleles had a lower tumor incidence and higher survival rate when compared with CD4-Rgr progeny with homozygous or heterozygous expression of p15 INK4b . Also, a similar survival pattern was observed in a parallel model in which transgenic mice expressing a constitutively activated N-Ras mutant were crossed into a p15 INK4b -deficient background. To analyze this paradoxical event, we investigated the hypothesis that the absence of both p15 INK4b alleles in the presence of the Rgr oncogene could be deleterious for proper thymocyte development. When analyzed, thymocyte development was blocked at the double negative (DN) 3 and DN4 stages in mice missing one or both alleles of p15 INK4b , respectively. We found reduction in overall apoptotic levels in the thymocytes of mice expressing Rgr, compared with their wild-type mice, supporting thymocyte escape from programmed cell death and subsequently facilitating the onset of thymic lymphomas but less for those missing both p15 alleles. These findings provide evidence of the complex interplay between oncogenes and tumor suppressor genes in tumor development and indicate that in the lymphoid tissue the inactivation of both p15 alleles is unlikely to be the first event in tumor development.
Introduction
Ras proteins are small GTPases that cycle between an active guanosine triphosphate (GTP)-bound and an inactive guanosine diphosphatebound state. The active and inactive states are controlled by guanine nucleotide exchange factors (GEFs) that stimulate the release of bound guanosine diphosphate and by GTPase activating proteins that initiate the hydrolysis of the gamma phosphate group, rendering Ras inactive. The stimulation of cellular growth or transformation by constitutively activated Ras (through increased GEF activity or decreased GTPase activating protein reactivity) in a normal cell can induce tumor suppressor mechanisms resulting in apoptosis or cellular senescence (1, 2) .
Cyclin dependent kinase inhibitors (CDKis), which consist of the INK and CIP/KIP families, protect cells by blocking oncogenic signals that initiate cellular transformation. Signals elicited by oncogenic Ras can lead to increased levels of p16 INK4a , p21 CIP1 , p19 ARF and/or p53, which are followed by cellular growth arrest during the G 1 phase of the cell cycle (3, 4) . Additional work has demonstrated that p15 INK4b , another member of the INK4 family, can be induced by oncogenic Ras and is also associated with G 1 arrest and cellular senescence (5) . The inactivation of the INK4a and INK4b loci has been observed in a wide variety of human malignancies and murine tumor models (6) (7) (8) (9) . Currently, two significant mechanisms of CDKi inactivation have been reported in various malignancies-homozygous deletion (10) (11) (12) and promoter silencing by methylation (13) (14) (15) (16) (17) .
The Ral GDS-related (Rgr) oncogene was isolated and analyzed in our laboratory through gene transfer using DNA from a 7,12-dimethylbenz(a)anthracene-induced rabbit squamous cell carcinoma followed by nude mouse tumorigenesis assays (18) . Rgr was initially characterized as a GEF for Ral GTPases (18) ; however, it has been found to function as a GEF for Ras GTPases (19) . We previously reported that increased Ras activation induced by the introduction of Rgr into murine fibroblasts resulted in anchorage independence, reversal of contact inhibition, abnormal cellular morphology as well as increased phosphorylation of p38 and c-Jun (20) . It was further determined that the oncogenic nature of Rgr is caused by its overexpression, resulting from elimination of translational regulatory elements in the 5# untranslated region (21) . The human ortholog to Rgr, hRgr, was detected and isolated from a T-cell acute lymphoblastic leukemia (T-ALL)-derived cell line and it was found to have a similar overexpression through the elimination of its 5# untranslated region and a large portion of its coding sequence (22) .
Utilizing an Rgr transgenic model, in which the expression of Rgr is driven by an MSV promoter, we found that the expression of Rgr resulted in several phenotypic irregularities, including cataracts of the lens, Harderian gland adenomas, inguinal hernias and fibrosarcomas located in hind limbs and tail (23) . This study concluded that the expression of Rgr combined with the absence of p15 INK4b in a transgenic/knockout model exacerbated the incidence of fibrosarcomas in these mice, demonstrating the synergistic cooperation between Rgr and the absence of p15 INK4b in vivo (23) .
In this study, we wanted to investigate the phenotypic effects caused by the allelic ablation of p15 INK4b promoting thymic lymphomas given the role that this tumor suppressor has in human leukemias and lymphomas, where it has been shown to be frequently inactivated in ALL (24) AML (25) , B-and T-cell lymphomas (26) and myelodysplastic syndrome (27) . In many of these tumors, p15 INK4b is more frequently inactivated than p16 INK4a (26) (27) (28) (29) . Surprisingly, we found that the loss of both p15 INK4b alleles led to lower tumor incidence in the CD4-Rgr Â p15 INK4bÀ/À transgenic/knockout murine model when compared with transgenic mice possessing one or two p15 INK4b alleles. Further analyses from this novel murine model have revealed that the loss of both p15 INK4b alleles caused alterations in thymocyte development and apoptotic events that could be the basis for this paradoxical result.
Materials and methods
Generation and genotyping of transgenic/knockout mice p15
INK4bÀ/À and CD4-Rgr mice, described previously (23), were mated together to create the CD4-Rgr Â p15
INK4bÀ/À transgenic/knockout line. To generate a congenic line, p15
INK4bÀ/À mice, which were maintained in a 129/Sv Â C57BL6 genetic background, were backcrossed into FVB/N inbred strain for eight generations and then mated with CD4-Rgr mice as described above. All mice were genotyped by PCR amplification of tail genomic DNA extracted by alkaline lysis (30) using previously described primers (23, 31) . Mice were monitored for the development of thymic lymphomas and subsequently euthanized upon signs of labored breathing. The N-RasT transgenic mice were generated as described previously (32) and the N-Ras Â p15
INK4bÀ/À were generated as described above. These mice were kept in accordance with approved Institutional Animal Care and Use Committee protocols at New York University School of Medicine.
Western blotting
Protein extracts were isolated from the thymi of 6-to 8-week old mice and western blotting was performed as described previously (33) . Membranes were blocked for 1 h with Odyssey Blocking Buffer (LI-COR Biosciences) and were incubated with the appropriate antibodies at 1:1000 dilutions for the FLAG Abbreviations: CDKi, cyclin-dependent kinase inhibitor; DN, double negative; GEF, guanine nucleotide exchange factor; GTP, guanosine triphosphate. epitope (Sigma) and Cullin 1 (Invitrogen). Then, the membranes were incubated with IRDye 800 anti-goat IgG (LI-COR Biosciences) at a 1:10 000 dilution and scanned on an Odyssey imager (LI-COR Biosciences). When necessary, the membranes were subjected to densitometry with the Odyssey Application software, version 3.0 (LI-COR Biosciences).
Active Ras GTPase pull-down and detection Activated Ras was determined using the Active Ras Pull-Down Detection Kit (Thermo Fisher Scientific), according to the manufacturer's protocol. Briefly, proteins extracted from the thymi of 6-week old mice were incubated with 80 lg of GST-Raf 1-Ras binding domain protein agarose beads for 1 h at 4°C. GST-bound proteins were washed twice with washing buffer and eluted with 50 ll 2X Laemmli sample buffer, detected by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred to a PVDF membrane for western blotting with a mouse anti-Ras monoclonal antibody, provided with the kit.
Isolation of double negative thymocytes
To isolate the double negative (DN) thymocyte subset, single positive (SP; CD4 þ and CD8 þ ) and double positive (DP; CD4 þ CD8 þ ) cells were depleted from the total thymocyte population. Approximately, 1 Â 10 7 thymocytes from 6-to 8-week old mice were prepared as a single cell suspension by homogenization with the aid of a 30 lm metal nylon mesh. Single cell suspensions were subjected to magnetic activated cell sorting (MACS; Militenyi Biotech), according to manufacturer's protocols. Briefly, single cell suspensions were incubated with CD8a (Ly-2) and CD4 (L3T4) microbeads (Militenyi Biotech) and loaded onto a MACS LD column. The flow through from three fractions was collected and applied to downstream procedures, mentioned below. 5 ) were stained with the following antibodies (all from eBiosciences): 0.126 lg allophycocyanin (APC)-labeled anti-CD25 (IL-2; clone PC61.5) and 0.126 lg APC-eFluor anti-CD44 (clone IM7) antibodies for 1 h at 4°C in the dark. At least 30 000 events were collected using an LSR II flow cytometer (BD Biosciences) and analyzed using FACSdiva (BD Biosciences) software. To ensure the elimination of SP and DP populations in the preliminary experiments, the MACS separated DN thymocytes were stained with 0.05 lg Phycoerythrin (PE)-Cy7 anti-CD8a (clone 53-6.7) and 0.05 lg PE-Cy7 anti-CD4 (clone GK1.5), as described herein.
Analysis of DN T-cell stages
DN thymocytes (1 Â 10
Apoptosis detection
The characterization of apoptosis in the CD4-Rgr Â p15 INK4bÀ/À model was determined by using the Annexin V Apoptosis Detection Kit (BD Bioscience), according to the manufacturer's protocol. Briefly, 1 Â 10 5 DN thymocytes harvested from 6-week old mice were stained with either 5 ll of Annexin V, 7-Aminoactinomycin D (7-AAD) or Annexin V and 7-AAD for 1 h at room temperature in the dark. Flow cytometric analysis was performed for at least 20 000 events using an LSR II flow cytometry and FACSdiva software.
Statistical analysis
Survival analysis was performed by using the Kaplan-Meier method. Survival curves were compared and differences in survival were tested for significance by using a log-rank test (GraphPad). Analysis of variation in conjunction with the Tukey and Bonferroni post hoc tests (GraphPad) were used to analyze statistical significance between a control group and experimental groups, with Ã representing P , 0.05; ÃÃ P , 0.01 and ÃÃÃ P , 0.001.
Results
Incidence rate of thymic lymphomas in CD4-Rgr Â p15 INK4b-/-progeny Mice harboring the CD4-Rgr transgene succumbed to thymic lymphomas at a faster rate and had reduced survival when compared with their wild-type counterparts. These data, along with previously reported data, confirm that increased activation of Ras (in this case, mediated by the overexpression of Rgr) can reduce mouse survival (23, 34) . Surprisingly, we found that mice with the complete absence of p15 INK4b (Rgr-p15 À/À ) had a higher survival rate (lower lymphoma incidence) compared to that of CD4-Rgr transgenic mice with homozygous (Rgr) or heterozygous (Rgr-p15 þ/À ) expression of p15 INK4b ( Figure 1A ). The differences in survival (tumor incidence) were found to be significant (P 5 0.007), as determined by the log-rank test. We detected high levels of protein expression of Rgr in the thymus and spleen of the CD4-Rgr Â p15 iNK4b-/-progeny ( Figure 1B ), confirming the expression of Rgr in immunological tissues. As expected, the Rgr transgenic mice developed tumors that were characterized by significant increases in their thymi size ( Figure 1C ), however we did not observe any significant differences in the wet weights of the thymi and spleens among the various Rgr transgenic genotypes ( Figure 1C) . A similar unexpected phenomenon of lower tumor incidence in mice lacking both p15 INK4b alleles was observed in our other transgenic/knockout murine model, in which N-RasT transgenic mice were crossed into a p15 INK4b -deficient background. These mice express a constitutively active form of N-Ras (N-RasT), created by the introduction of a point mutation at codon 61, which renders Ras unresponsive to GTPase activating protein activity. Here, we found that the majority of mice with the absence of both p15 INK4b alleles (N-RasT-p15 À/À ) had a lower incidence of lymphomas when compared with that of mice expressing both p15 alleles (N-RasT) and especially with only one p15 allele (N-RasT-p15 þ/À ) ( Figure 2A) . As determined by the log-rank test, the survival patterns of this murine line were found to be significant (P 5 0.002). Consistent with the data shown in Figure 1 , N-RasT-p15 þ/À mice had a higher number of thymic lymphomas ($60%) when compared with the Figure 2B ). In addition, N-RasT-p15 À/À mice displayed longer latency in tumor development ( Figure 2C ). These data suggest that upon the increased expression or constitutive activation of an oncogene (Rgr or N-Ras, respectively) combined with the complete ablation of a tumor suppressor gene (p15 INK4b ) thymocyte development may be altered, resulting in a lower predisposition to thymic lymphoma development as exemplified by lower tumor incidence and longer latency (Figure 2A ).
The complete ablation of p15 INK4b alleles does not dramatically affect Ras GTPase activation
To investigate if the loss of both p15 INK4b alleles could have an effect of modifying Ras activation to explain the changes in tumor incidence, we performed active Ras GTPase pull-down assays on protein lysates extracted from the thymi of the six progeny genotypes expanded from the CD4-Rgr Â p15 INK4b-/-line at 6-8 weeks of age ( Figure 3A and B).
As expected, the Rgr-transgenic progeny had higher levels of Ras GTPase activation (P , 0.05) compared with the levels of the nontransgenic counterparts ( Figure 3A and B). Specifically, there was at least a 2.5-fold increase in Ras activation for Rgr transgenic mice when compared with that of wild-type (WT) mice. Additionally, we did not find any significant differences in Ras activation between the CD4-Rgr Â p15 INK4b-/-progeny lacking the expression of Rgr (WT, p15 þ/À and p15 À/À ; Figure 3A ). More importantly, there were no significant differences in Ras activation levels between the three genotypes in which Rgr expression results in the development of thymic lymphomas. Based on these data, additional events resulting from the activation of Ras (through Rgr overexpression) must take place in order to modify tumor incidence.
Rgr cooperates with p15 INK4b in altering thymocyte development We sought to determine the role that Rgr and the presence or absence of one or both p15 INK4b alleles has on controlling thymocyte maturation during DN stages of development. The DN period of thymocyte development is marked by four separate stages based on the expression patterns of CD25 and CD44 surface markers: (35) . In MACS-isolated DN thymocytes, we found that Rgr expression in the presence of one or both alleles of p15 INK4b (Rgr-p15 þ/À and Rgr, respectively) elicits a block in T-cell development in distinct DN stages (Figure 4 ). More specifically, we observed a substantial blockage in the DN3-DN4 transition for Rgr-p15 þ/À mice, as compared with that of their wild-type counterparts. In thymocytes with a complete ablation of p15 INK4b , we found a shift in the thymocyte developmental program that exhibited a reduction in cellular progression through the DN4 stage ( Figure 4) . Additionally, in DN1, there appears to be a lower number of cells in Rgr-expressing mice when both p15 alleles are missing. These results suggest that p15 INK4b does have a relevant role in thymocyte INK4b alleles was associated with longer latencies.
Fig. 3. Rgr increases the levels of GTP-bound (active) Ras in the thymus. (A) Cumulative analysis of activated Ras in Rgr Â p15
INK4b-/-progeny relative to wild-type mice in three independent experiments; Ã P , 0.05. (B) A representative experiment for Ras activation in which protein lysates (500 lg) extracted from the thymii of 6-week old mice were used to recover the GTP-bound forms of Ras (with GST-Raf1-Ras binding domain). Total Ras and Culin-1 (middle and bottom, respectively) present in 20 lg of whole cell lysate for the activation assays.
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development and that there is a collaborative relationship with Ras activation. These results indicate that modifications of p15 INK4b expression have a role in thymocyte development, which is influenced by the activation of Ras.
Thymocyte apoptosis can be modulated by the expression of rgr and the ablation of p15 INK4b Since the initiation of thymic lymphomas may be facilitated by a decrease in apoptotic events, the effect of an oncogene (Rgr) and of allelic disruption of a tumor suppressor (p15 INK4b ) on apoptosis was analyzed. Using DN-isolated thymocytes from 6-to 8-week old mice, we determined that the presence of Rgr reduced apoptotic events in pre-tumorigenic thymocytes ( Figure 5A and B) , as it would be expected for mice that harbor an expressing oncogene in this lineage of cells. Additionally, we found that there were a greater number of viable thymocytes from the Rgr-p15 þ/À progeny (62% of total cell population) when compared with those from other genotypes ( Figure 5A ). These data are consistent with the observation that Rgr-p15 þ/À mice subsequently develop a higher incidence of tumors ( Figure 1A) . We also found that the Rgr-p15 À/À progeny had a higher number of thymocytes in late apoptosis, suggesting that this genotype may produce less lymphomas if a subset of these cells undergoing apoptosis are the same that would serve as potential tumor precursors. Interestingly, we found that the Rgr-p15 À/À progeny had the smallest change in apoptotic levels (23%) when compared with its wild-type counterpart (p15 À/À , Figure 5B ), indicating that more apoptotic events occur with Rgr expression and the complete ablation of p15 INK4b . For Rgr and Rgr-p15 þ/À versus their wild-type counterparts, the change in the combined apoptotic events was 49% and 33%, respectively ( Figure 5B ). These data suggest that both the expression of an oncogene in the presence of at least one allele of p15 INK4b decreases apoptotic events and facilitates tumor Fig. 4 . Expression of Rgr in combination with presence or complete ablation of both p15 alleles modifies T-cell development in different stages. DN thymocyte (1 Â 10 5 ) population was subjected to staining and flow cytomentry analysis using antibodies against CD25 and CD44 to monitor thymocyte phenotypes during the DN stages of thymocyte development. Here, we found that Rgr and Rgr-p15 þ/À mice displayed more drastic defects of T-cell development during the DN3-DN4 transition stage; while Rgrp15 À/À mice exhibited a similar defect during DN4-double positive (DP) stage. These data represent five independent experiments, in which at least two mice from each genotype were used with Ã P , 0.05; ÃÃ P , 0.01 and ÃÃÃ P , 0.001. development. Also, the complete absence of p15 INK4b , in the presence of a potent oncogene (Rgr), increases programmed cell death (compared with wild-type counterparts) thus reducing tumor incidence.
Discussion
We previously reported that the complete ablation of p15 INK4b in combination with Rgr expression driven by the MSV promoter resulted in increased fibrosarcomas and adenomas (23) . In this previously described murine model, Ras activation is induced by Rgr expression, which has been isolated in our laboratory and described as a GEF for Ras and Ral GTPases (18, (20) (21) (22) . In this study, we have created the CD4-Rgr Â p15 INK4b-/-transgenic/knockout murine model to further investigate the effect that an activator of Ras in combination with p15 INK4b deficiency would have on thymic lymphoma initiation. Aberrant Ras activation has been identified in a wide array of neoplasms, including those of the lymphoid and myeloid lineages. Ras signaling in lymphocytes has been linked to proper relay of antigen receptor signals during thymocyte development (36), T-cell anergy (37) , antigen receptor function in the periphery (38) and the regulation of transcription factors that control the expression of cytokine genes, such as Elk-1, SRF, AP1 and NFAT family members (39, 40) . In human hematological malignancies, mutations that cause constitutive activation of Ras have been observed in acute myeloid leukemias, juvenile myelomonocytic leukemias and acute lymphoblastic leukemias (2) .
Inactivation of the INK4 family of tumor suppressors (p16 INK4a / p14 ARF , p15 INK4b , p18 INK4c and p19 INK4d in humans), caused by mutation and/or epigenetic silencing events, has been observed in many types of malignancies (10, 13, 14, 16, (41) (42) (43) . The INK4 family of CDKis serve as tumor suppressors by inhibiting the formation of cyclin D and cdk4 or cdk6 complexes, thus preventing entry into the S phase of the cell cycle (44) . Clinical studies, as well as murine models, have demonstrated that p15 INK4b silencing through promoter methylation or deletion is implicated in both lymphoid and myeloid malignancies and in many of these malignancies p15 INK4b is the INK4 family member preferentially inactivated (45, 46) . Additionally, demethylation of hypermethylated p15 INK4b by 5-Aza-2#-deoxycytidine (decitabine) treatment was shown to reduce cytopenias and blast excess in patients diagnosed with myelodysplastic syndrome (47) .
In the present study, we focused on the role that the heterozygous or homozygous ablation of p15 INK4b combined with the presence of increased Ras activity by either Rgr expression or N-Ras mutation would have on lymphoma initiation and development. The Rgr Â p15 INK4b-/-transgenic/knockout murine model is useful to our understanding of thymocyte development because our knowledge concerning the function of p15 INK4b in lymphoid organs is very limited. Surprisingly, we found that the presence of Rgr (resulting in increased Ras activation) and the absence of both p15 INK4b alleles appear to improve the survival of these mice compared with their Rgr and Rgrp15 INK4bþ/-counterparts ( Figure 1A) . We also observed a similar pattern in our other transgenic/knockout murine model, in which mice with a constitutively active form of N-Ras were crossed into a p15 INK4b -deficient murine line (Figure 2 ). One possible explanation for this paradoxical event is that in the presence or activation of a strong oncogene (in this case, Ras) and the loss of both alleles of a tumor suppressor gene (p15 INK4b ) could produce alterations in proper thymocyte development and eliminate a higher proportion of the predestined neoplastic precursors from the thymocyte repertoire.
Similar to other malignancies, thymic lymphomas are initiated by the activation of oncogenes combined with the loss of tumor suppressor genes leading to stalled thymocyte development and abnormal proliferation. During thymic development, lymphoid precursors undergo consecutive stages of differentiation, expansion and selection (48) . DN subset of thymocytes, which represent 1-5% of the total thymocyte population, can be resolved into four separate stages based on surface expression of CD44 and CD25 (DN1:
CD25 À CD44 þ and DN4: CD25 À CD44 À ). Normal signaling through DN3 is critical for proper thymocyte development, in which the T-cell receptor b gene rearrangements (b-selection checkpoint) occur, prompting correct signaling through DN4 to the double positive (DP; CD4 þ CD8 þ ) stages (49, 50) . Here, we found the activation of Ras with one or both alleles of p15 INK4b caused a substantial block at the DN3-DN4 transition of development (Figure 4) . The DN4 and DP stages of thymocyte development are marked by T-cell receptor a chain rearrangement, a point that is extremely critical for death by neglect, death by negative selection and positive selection in thymocytes (51) . Here, we found a substantial increase in DN4 thymocytes with the homozygous deletion of p15 INK4b in the presence of Rgr (Rgr-p15 À/À ). Additionally, a similar trend for the DN4 stage was observed for p15 À/À mice, suggesting that both alleles of p15 INK4b are necessary for progression into the DP stage of thymocyte development. Perhaps, the ablation of both p15 INK4b alleles causes delays in T-cell receptor a rearrangements, which determines the reactivity of fully formed T-cell receptors (51) and changes in p15 INK4b expression deregulate necessary checkpoints for proper thymocyte maturation.
The data we present in this study demonstrate that allelic disruption of p15 INK4b does have a role in thymocyte development and can affect the induction of thymic lymphomas in mice, which is consistent with our previous results indicating that p15 INK4b is an important tumor suppressor gene in these lymphomas (52, 53) and in human hematopoietic malignancies (29, 54, 55) . Moreover, we show that in the thymus, the loss of both p15 INK4b alleles in the presence of an oncogene may lead to increased apoptotic levels within the DN thymocyte population ( Figure 5 ). Increased apoptosis results in a decrease in the tumorigenic phenotype, marked by longer latency, stalled thymocyte development and higher levels of apoptosis versus their normal counterparts.
Another CDKi, p21 Waf1/Cip1 , is involved in the inhibition of CDK2 association or binding to cyclins A and E during the G1-S transition of the cell cycle (56, 57) . The regulation of p21 Waf1/Cip1 is controlled by p53, a tumor suppressor, whereby the activation of p53 induces p21 expression, resulting in cell cycle arrest (56, 57) . Additionally, deletions of p21 Waf/Cip1 in mice have been correlated with increased tumorigenesis in hematopoietic, endothelial and epithelial tissues (58) . A study performed by De la Cueva et al. (59) found that p53-and p21 Waf1/Cip1 -deficient mice had longer survival, lower lymphoma incidence and increased apoptosis when compared with p53-deficient and p21 Waf1/ Cip1þþ mice. The results in this study are somewhat similar to our observations in that the complete ablation of a CDKi in combination with the loss of a tumor suppressor or the expression of an oncogene can result in delayed induction of murine thymic lymphomas.
This study provides novel information to understand the role of p15 INK4b , a CDKi that is frequently overlooked in lymphoid development and tumorigenesis and to elucidate the potential sequence of events in tumor development. In this system, the inactivation of both p15 INK4b alleles may serve as a protective mechanism against lymphoma development when Ras is activated, suggesting that the inactivation of both alleles of p15 INK4b is unlikely to be the initiating transforming event. More likely, either Ras activation or the loss of only one p15 allele precede the total inactivation of p15 INK4b leading to malignancies within lymphoid tissues. Since we have recently reported the activation of hRgr in a significant subset of human T-cell malignancies (19) , it would be useful to investigate the status of p15 INK4b in those malignancies to ascertain if there is an interplay between these two genes in humans.
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